Orchard Therapeutics PLC
Koval Smith, PhD, currently serves as Associate Director of MSAT at Orchard Therapeutics, with a career spanning various roles in manufacturing science and technology within the biotech sector. Prior to this position, Koval worked as a Senior Scientist and Senior Manager at Autolus Ltd., focusing on CART process development and managing training for GMP staff. Academic experience includes a postdoctoral role at Imperial College London researching vascular sciences and a PhD in Clinical Medicine Research from the same institution. Additional relevant experience encompasses positions in phlebotomy and bioscience review, complemented by a strong educational background in human and medical sciences.
This person is not in any teams
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.